Omega Diagnostics Group PLC Confirmation of detection of Omicron variant
10 Enero 2022 - 9:20AM
RNS Non-Regulatory
TIDMODX
Omega Diagnostics Group PLC
10 January 2022
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Confirmation of detection of Omicron variant
VISITECT(R) COVID-19 antigen test performs with the same high
accuracy on the Omicron variant
Omega (AIM: ODX), the specialist medical diagnostics company
focused on industry-leading Global Health (CD4 and COVID-19) and
Health and Nutrition products, notes concerns regarding the ability
of certain lateral flow tests to detect the Omicron variant with
the same sensitivity for lower viral loads.
Further to the announcement on 14 December 2021 , the Company's
technology partner Mologic Ltd ("Mologic") has today re-confirmed
that the Mologic Covios(R) Ag lateral flow test, performs with the
same high accuracy on the Omicron variant as it does with existing
known variants.
Mologic's studies are ongoing to determine the absolute
performance of the test across the use case settings and in
laboratory environments to produce a comprehensive analysis of the
detection of Omicron. No data exists to suggest there is an issue,
be that in silico or in trials.
This is the same test that is manufactured and sold for
professional use by Omega as the VISITECT(R) COVID-19 antigen
test.
Contacts:
Omega Diagnostics Group PLC www.omegadx.com
Colin King, Chief Executive Officer via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate
Finance)
Alice Lane/ Charlotte Sutcliffe (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro
diagnostic products for use in hospitals, clinics, laboratories and
healthcare practitioners in over 75 countries and specialise in the
areas of health and nutrition and global health.
www.omegadx.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFLELAIILIF
(END) Dow Jones Newswires
January 10, 2022 10:20 ET (15:20 GMT)
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024